The abstract is read at the publisher; the summary is JClub's.
Targeting regulatory T cells in cancer is linked to antitumor effects in preclinical studies, but clinical trials show variable efficacy and toxicity due to immune balance constraints.
- Why it matters: Tregs maintain immune tolerance yet can be co-opted by tumors, and high tumor microenvironment Treg infiltration is linked to variable prognosis across tumor types.
- What they did: A targeted literature review (PubMed/MEDLINE, Web of Science, ClinicalTrials.gov, and ASCO/ESMO meeting libraries) summarized strategies including Treg depletion (anti-CD25, anti-CCR4, anti-CCR8), functional blockade (CTLA-4, TIGIT), and metabolic disruption (adenosine, PI3K).
- The result: Newer approaches aim to selectively impair intratumoral Tregs while preserving peripheral control, guided by T-cell subset markers such as FOXP3 + Helios + CCR8 + cells to help predict therapeutic response.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.